FLT3 and kidney cancer: Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, FLT3 internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia (AML), and radioactive iodine resistant advanced thyroid carcinoma.